Inventor · disambiguated record
Alexandre Vamvakides
Also filed as: VAMVAKIDES ALEXANDRE
2 granted patents·11 pending applications·13 citations·filing 2008–2017
59Inventor score
Top patents by PatentIndex Score
13 records- 0184US9750746B2ANAVEX2-73 and certain anticholinesterase inhibitors composition and method for neuroprotectionANAVEX LIFE SCIENCES CORP·Filed 2013·Granted Sep 5, 2017·7 cites·2 claims
- 0277US9180106B2Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anti-cancer activityANAVEX LIFE SCIENCES CORP·Filed 2014·Granted Nov 10, 2015·6 cites·16 claims
- 0358US2017360798A1Anavex2-73 and certain anticholinesterase inhibitors composition and method for neuroprotectionANAVEX LIFE SCIENCES CORP·Filed 2017·Application pending·0 cites
- 0456US2015073046A1Optimization and therapeutic valorization of the symptomatic treatment of alzheimer's disease with rivastigmine, galantamine or donepezil, by selected aminotetrahydrofurans acting as mixed sigma-1 / muscarinic ligandsVAMVAKIDES ALEXANDRE·Filed 2013·Application pending·0 cites
- 0551US2016009674A1Prototypical brain protective activity of tetrahydro-n-methyl-2,2-diphenyl-3-furanomethanamine (ae37met)VAMVAKIDES ALEXANDRE·Filed 2015·Application pending·0 cites
- 0645US2010069484A1SIGMA(s)-RECEPTOR LIGANDS WITH ANTI-APOPTOTIC AND/OR PRO-APOPTOTIC PROPERTIES OVER CELLULAR BIOCHEMICAL MECHANISMS, WITH NEUROPROTECTIVE, ANTI-CANCER, ANTI-METASTATIC AND ANTI-(CHRONIC) INFLAMMATORY ACTIONVAMVAKIDES ALEXANDRE·Filed 2008·Application pending·0 cites
- 0739US2017129864A1New sigma-receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular biochemical mechanisms with neuroprotective, anti-cancer, anti-metastatic and anti-(chronic) inflammatory actionVAMVAKIDES ALEXANDRE·Filed 2013·Application pending·0 cites
- 0834US2018235914A1Prototypical molecular pharmacologic profile of lipophilic gabaergic a & b agonists against neurodegenerative and neurodevelopmental diseasesVAMVAKIDES ALEXANDRE·Filed 2017·Application pending·0 cites
- 0932US2011301154A1Sigma receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anticancer activityVAMVAKIDES ALEXANDRE·Filed 2010·Application pending·0 cites
- 1031US2017071879A1Prototypical analgesic profile of 3,3-diphenyl-n-(1-phenylethyl)propan-1-amine (fendiline)VAMVAKIDES ALEXANDRE·Filed 2015·Application pending·0 cites
- 1131US2015126611A13,3-diphenyl-n-(1-phenylethyl) propan-1-amine: as a new selective ligand of the sigma-1 receptors, with anti-apoptotic (cytoprotective) properties and prototypical anticancer activityALEXANDRE VAMVAKIDES·Filed 2013·Application pending·0 cites
- 1230US2016367505A1Prototypical analgesic profile of n-stearyl dopamine (ns-da)VAMVAKIDES ALEXANDRE·Filed 2015·Application pending·0 cites
- 1328US2018193289A1Prototypical molecular pharmacologic profile of fendiline against neurodegenerative and neurodevelopmental diseasesVAMVAKIDES ALEXANDRE·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Alexandre Vamvakides files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →